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ABSTRACT 
 
Immunoglobulin G (IgG) is a central mediator of host defense due to its ability to 
recognize and eliminate pathogens. The recognition and effector responses are encoded 
on distinct regions of IgGs. The diversity of the antigen recognition Fab domains 
accounts for IgG’s ability to bind with high specificity to essentially any antigen. Recent 
studies have indicated that the Fc effector domain also displays considerable 
heterogeneity, accounting for its complex effector functions of inflammation, modulation 
and immune suppression. Therapeutic anti-tumor antibodies, for example, require the 
pro-inflammatory properties of the IgG Fc to eliminate tumor cells, while the anti-
inflammatory activity of Intravenous Immunoglobulin G (IVIG) requires specific Fc 
glycans for activity. In particular, the anti-inflammatory activity of IVIG is ascribed to a 
small population of IgGs in which the Asn297-linked complex N-glycans attached to 
each Fc CH2 domain include terminal 2,6-linked sialic acids. We used chemoenzymatic 
glycoengineering to prepare fully di-sialylated IgG Fc and solved its crystal structure. 
Comparison of the structures of asialylated Fc, sialylated Fc, and F241A Fc, a mutant 
that displays increased glycan sialylation, suggests that increased conformational 
flexibility of the CH2 domain is associated with the switch from pro- to anti-inflammatory 
activity of the Fc. 
 
KEYWORDS 
 
sialylated IgG Fc, inflammation, IVIG, N-linked glycan, X-ray crystallography   
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INTRODUCTION 
IVIG is used worldwide as an antibody replacement therapy and as a treatment for a 
variety of inflammatory disorders [1]. IVIG is pooled IgG from the serum of healthy 
donors. It contains the four different subtypes of human IgG (IgG1, IgG2, IgG3, and 
IgG4) and over 30 glycovariants [2]. Although the beneficial effects of IVIG as an anti-
inflammatory preparation are apparent, the mechanism of action has only recently begun 
to be understood as being correlated with the relatively constant portion, or Fc region, of 
IgGs [3]. The Fc region of IgG interacts with a variety of receptors, determined by the 
amino acid and glycan composition of the Fc. Among these receptors are the canonical 
FcRs: four are activating (FcRI, FcRIIA, FcRIIIA, FcRIIIB) and one is an inhibitory 
receptor (FcRIIB) [3]. The simultaneous expression of these receptors on effector cells 
sets a threshold for inflammatory responses [4]. IVIG causes an up-regulation of the 
inhibitory receptor FcRIIB, initiating anti-inflammatory responses [5]. 
A downside of IVIG therapy is that it is only effective when administered at high 
doses (1-3 g/kg) when treating inflammatory diseases [6]. Rationalizing the high dose 
requirements, the anti-inflammatory activity of IVIG has been attributed to a small 
population of IgGs with 2,6-sialyated N-linked glycans attached to a conserved 
asparagine (Asn297) in the Fc CH2 domain [7]. The Asn297-linked carbohydrate is a 
complex, usually core-fucosylated, biantennary glycan containing a pentasaccharide 
Man3GlcNAc2 core (Man, mannose; GlcNAc, N-acetylglucosamine), which can be 
modified by addition of terminal galactose or sialic acid [8] (Fig. 1).  Approximately 10% 
of the Fc regions in IVIG terminate in sialic acid, of which 1-3% are disialylated [2; 9; 10]. 
In vivo studies have shown that Fc sialylation is the main determinant in IVIG anti-
inflammatory activity [9; 11]. For example, IVIG that was enriched in terminally-sialylated 
Fc glycans showed a 10-fold increase in anti-inflammatory activity [7; 12], and if IVIG 
was treated with neuraminidase to remove terminal sialic acids or with PNGase F to 
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remove the entire N-linked glycan, the anti-inflammatory activity of IVIG was abrogated 
[9]. Similar results were found for recombinant, 2,6 sialylated IgG1 [7]. In mouse models, 
including a serum-induced arthritis model in mice, sialylated Fc (sFc; defined here as 
referring to a mixture of sialylated glycoforms) decreased inflammation of ankle joints [9], 
and IVIG activity was shown to be dependent upon terminally-sialylated Fc regions in 
four independent in vivo model systems of autoimmune disease mediated by auto-
antibodies [11]. 
The anti-inflammatory properties of sFc have been attributed to the effect of 
sialylation switching the specificity of Fc binding to its receptors. In vivo experiments 
showed that the anti-inflammatory effects of sFc required expression of the C-type lectin-
like receptor specific intracellular adhesion molecule-grabbing non-integrin R1 (SIGN-RI) 
(the mouse homolog of human dendritic cell-specific intercellular adhesion molecule-3-
grabbing nonintegrin; DC-SIGN), leading to a model in which conformational changes in 
Fc resulting from sialylation of the Asn297-attached glycan allowed interactions with 
members of the SIGN receptor family [13]. Indeed, previous structural studies 
demonstrated that modification of the Asp297-linked glycan can affect Fc structure. For 
example, it was shown that the glycan contributed to an “open” conformation of IgG Fcs, 
in which the CH2 domains were separated by a larger distance than in deglycosylated Fc 
structures [14]. If the IgG Fc glycan was enzymatically removed, the CH2 region adopted 
a “closed” state [15]. Conformational changes have also been observed when individual 
sugar residues on the Fc-linked glycan were modified. When fucose was removed, a 
subtle change involving Tyr296 was observed in X-ray crystallographic and NMR 
structures [16; 17]. This modification resulted in an increased affinity for the activating 
receptor FcRIIIa, leading to enhanced antibody-dependent cellular cytotoxicity (ADCC) 
activity [18; 19]. Solution NMR studies have reported increased mobility of the glycan 
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arms upon sialylation, further supporting the contention that alterations in the glycan 
composition can influence the structure of the Fc [20]. 
Here we solved the crystal structure of a chemically-homogeneous disialylated 
Fc (di-sFc) and compared it to new structures of a partially sialylated Fc (F241A Fc) and 
wtFc, as well as to wtFc and glycomutant Fc structures available in the protein data bank 
(PDB). We found that di-sFc and F241A Fc show increased conformational 
heterogeneity in crystals compared to wtFc, a characteristic that may relate to sialylation 
and anti-inflammatory properties. 
 
RESULTS 
Glycan analysis of purified Fc proteins 
Proteins were produced by transient transfection in HEK 293-6E cells as IgG1 Fc 
fragments (wtFc, F241A Fc and F243A Fc) or in a stably-transfected Chinese hamster 
ovary (CHO) cell line (wtFc) [21]. Disialylated sFc (di-sFc) was prepared by 
chemoenzymatic glycoengineering [22] of an Fc fragment isolated after papain cleavage 
of Rituximab, a human IgG1.  
Carbohydrate analyses of N-glycans released from the Fc proteins revealed that 
the N-glycans attached to Asn297 of wtFc expressed in either HEK293 or CHO cells 
consisted of only three glycoforms: G0F, G1F, and G2F (Fig. 2a,b,). This result was 
consistent with previous studies investigating glycoforms of IgGs expressed in HEK cells 
[23]. Neither mono- nor disialylated N-glycans on either form of wtFc were detected. By 
contrast, the glycans attached to the F241A and F243A Fc mutants contained more 
diverse glycoforms: in addition to the G0F, G1F, and G2F glycoforms, significant 
portions of the N-glycans carried a bisecting GlcNAc moiety and contained terminal sialic 
acids (Fig. 2c,d,). The sialylated forms included about 20% of terminally monosialylated 
N-glycans (S1G2F and other monosialylated glycoforms) and about 4% of disialylated N-
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glycans (S2G2F and other disialylated glycoforms). These results were consistent with a 
recent study of the F241A and F243A Fc mutants [23], suggesting that these 
substitutions promote further processing of Fc glycans resulting in generation of 
sialylated and bisecting GlcNAc-containing glycoforms. The chemoenzymatically 
remodeled Fc (di-sFc) was almost homogeneous: >95% of the N-glycans were the 
disialylated glycoform (Fig. 2e, Fig. S1). 
 We also compared the Fc proteins in a Western blot using Sambucus Nigra 
(SNA), a lectin that binds preferentially to α2,6-linked sialic acid attached to a terminal 
galactose [24]. As expected, SNA blots of wtFc, F241A, F243A and di-sFc proteins 
demonstrated sialylation of di-sFc, F241A Fc and F243A Fc, but not wtFc (Fig. 3). These 
results were consistent with previous reports of partial sialylation of the N-glycans of 
F241A and F243A Fc [25]. 
Liquid chromatography/electrospray ionization mass spectrometry (LC-ESI-MS) 
was used to analyze wtFc that was expressed as an Fc fragment in HEK cells before 
and after complete removal of the N-glycans by PNGase F treatment. The analysis 
revealed two major species that were 950 and 1315 Da larger than the calculated 
molecular mass of the polypeptide backbone following PNGase F treatment, suggesting 
the existence of additional posttranslational modifications (Fig. S2a). A similar analysis 
of wtFc expressed in CHO cells revealed three major species that were 269, 922, and 
1218 Da larger than the calculated molecular mass of the polypeptide backbone (Fig. 
S2b). The results for the F241A Fc and F243A Fc proteins that were expressed in HEK 
cells were the same as the HEK-expressed wtFc (Fig. S2c,d). In contrast, an Fc 
fragment prepared from papain cleavage of an intact IgG1 (Rituximab) did not contain 
posttranslational modifications other than the N-glycans (Fig. S2e). A monosaccharide 
composition analysis on the recombinant Fcs after removal of the N-glycans with 
PNGase F revealed the presence of GalNAc, GlcNAc, Gal, and Neu5Ac (Fig. S3b,c), 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 7 
suggesting the existence of O-linked glycans. In contrast, the Fc fragment prepared from 
papain cleavage of Rituximab did not contain any monosaccharides after PNGase F 
cleavage (Fig. S3d). On the basis of the additional molecular mass (950 Da) in 
comparison with the polypeptide backbone, the major O-glycan on the HEK-expressed 
Fcs appeared to be a core 1 structure carrying two sialic acid residues [calculated mass 
for (Neu5Ac)2-Gal-GalNAc–H2O = 947.86 Da]. In the CHO-expressed wtFc, an additional 
mass of 1218 Da on the polypeptide backbone was observed. However, this additional 
mass does not correspond to typical O-glycan structures, implicating potential additional 
modifications on the core structures; e.g., acetylation on the sialic acid moieties. The 
detailed structures of the O-glycans remain to be determined. However, the lack of 
reactivity of HEK-expressed wtFc in the SNA blot (Fig. 3) demonstrated that there were 
no α2,6-linked sialic acids on the putative O-glycans. Since the hinge region of IgG 
where the O-glycans would likely be located is usually disordered in Fc crystal 
structures, these glycans (if present) would not be visible in published structures of 
recombinantly-expressed Fc fragments [23; 26; 27; 28]. Nor are there apparent 
differences in the structural properties of Fcs that correlate with whether they were 
expressed as Fc fragments versus prepared by cleavage of intact IgG (Table 1).  
The finding of putative O-glycans on proteins expressed as Fc fragments, but not 
on an Fc fragment derived by cleavage of intact IgG, could be explained if expression of 
Fc as a fragment allows access during biosynthesis by O-glycan-adding enzymes in the 
Golgi apparatus to a region of the IgG hinge that is inaccessible when intact IgG is 
trafficking through the Golgi. Although there were no apparent structural differences in 
Fcs as a function of whether or not they were produced in a form predicted to contain the 
putative O-glycan, these results suggest that functional studies employing Fcs 
expressed directly as fragments should compare results with Fcs derived by enzymatic 
cleavage of intact IgGs to rule out potential effects of unnatural O-glycosylation.  
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wtFc structures are relatively similar  
In order to assess potential conformational differences in Fc structures, we first 
compared wtFc structures available in the Protein Data Bank (PDB) and a 2.4 Å 
resolution wtFc structure solved in this study (space group P212121; one molecule per 
asymmetric unit) (Supplementary Table 1). We defined “wild type” as those Fc structures 
that were derived from IgGs or Fc fragments containing the naturally-occurring mixture 
of N-glycans attached to Asn297 when the protein was produced in mammalian cells, 
which included our new wtFc structure and PDB entries 1H3X, 3AVE, 2DTS, 3DO3, 
1FC1 and 1HZH. Fc fragments are homodimers in which the N-terminal CH2 domains 
contact each other through their Asn297-linked N-glycans, and the C-terminal CH3 
domains form a stable interface that is relatively constant between structures (Fig. 1b 
and 4a). Although the CH2 domain N-glycans are generally heterogeneous in wtFc 
proteins (Fig. 2), ordered electron density is usually observed for eight or nine 
carbohydrate residues of the biantennary complex glycan attached to Asn297 of each 
CH2 domain (PDB codes: 1H3X, 3AVE, 2DTS, 3DO3, 1FC1 and 1HZH).  
In order to evaluate potential differences in wtFc and sialylated Fc structures 
(Fig. 4), the CH3 domains of the wtFc structures were aligned, and we monitored the 
separation of the CH2 domains as previously described [29] by measuring distances 
between the Catoms at CH2 positions 238, 241, 301, and 329. The differences in CH2 
domain separation (Table 1) relative to a published wtFc structure (3AVE) were plotted 
for each set of paired C positions (Fig. 5). Despite differences in crystal packing, the 
wtFc structures exhibited only small deviations in CH2 domain separation distances, 
demonstrating relatively little structural variability. By contrast, a low-resolution wtFc 
structure solved from crystals grown under high salt conditions [14] (PDB: 1H3Y) 
showed deviations from the other wtFc structures that were crystallized in lower salt 
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concentrations (Fig. 5, Table 1). Structures of Fc proteins with different defined 
glycoforms showed a larger degree of variability in CH2 domain separation than wtFc 
structures, as was also true for Fc structures with mutations introduced to enhance 
effector functions, and Fc structures solved as complexes with other proteins (Fig. 5). 
There were no systematic differences in CH2 domain separation or structure based on 
whether or not the Fc fragment was predicted to contain an O-glycan in its hinge region 
(Table 1; Fig. 5).  
 
Structures of two forms of di-sFc  
A 3.0 Å resolution of di-sFc was solved in space group P21 with two di-sFc molecules per 
asymmetric unit. The structure was compared with wtFc structures and a previously 
described structure of sFc that included a mixture of di- and monosialylated Fc (PDB: 
4BYH) [30]. In the di-sFc structure, electron density for biantennary N-linked glycans 
was visible for all four di-sFc chains in the two di-sFc dimers, but although the di-sFc 
protein was fully disialylated (Fig. 2e), electron density for a terminal sialic acid was 
found only on the 6-arm of chains B and C, with the 6-arm of chains A and D showing 
ordered glycan residues up to a GlcNAc or galactose, respectively, and the 3-arm 
showing electron density for glycan moieties up to the GlcNAc (chains A, B, C and D) 
(Fig. 6). Similarly, sialic acid was visible only on the 6-arm of chain A in the 4BYH sFc 
structure [30]. In all three sFc structures (in 4BYH as well as in the two copies of di-sFc 
in the new sFc structure), the 6- and 3-arms of the biantennary glycans projected away 
from the protein surface and were solvent exposed; thus the ordered sialic acid on the 
glycan 6-arm was not positioned into a pocket formed by Glu258 and Lys290, as 
previously proposed [13]. 
 Interestingly, the two di-sFc dimers in the asymmetric unit of the P21 crystals 
exhibited differences in the arrangement of their CH2 domains. One di-sFc (chains A and 
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B) exhibited a relatively “closed” conformation, as defined by the separation between the 
two CH2 domains, whereas the second di-sFc (chains C and D) exhibited a relatively 
“open” conformation (Table 1 and Fig. 4b). As compared with a representative wtFc 
structure (3AVE), the open di-sFc exhibited a 6.8 Å root mean square deviation (RMSD) 
(calculated for the 103 C atoms of one CH2 domain after alignment of the partner CH2 
domain in each structure), as compared a 15.0 Å RMSD between the wtFc and closed 
di-sFc CH2 domains, a 7.9 Å RMSD between the open di-sFc and the 4BYH sFc, and a 
8.8 Å RMSD between the closed di-sFc and the 4BYH sFc. To quantitatively evaluate 
CH2-CH2 domain separation distances, which cannot be easily defined by a single 
number reflecting an average separation, we used a previously-defined metric in which 
the distance between four partner C atoms on each CH2 domain are measured 
(Pro238, Pro329, Phe241 and Arg301) and compared between structures [29]. In 
addition to determining CH2-CH2 separation distances for these C residues (Table 1), 
we calculated the differences relative to a reference wtFc structure (3AVE) to determine 
how greatly the various structures deviated from wtFc and other Fc structures. As 
defined by the distances between these C atoms, the closed di-sFc exhibited a greater 
difference in CH2 domain separation when compared to wtFc structures than 4BHY sFc, 
whereas the open di-sFc C exhibited a difference within the range observed for other 
wtFc structures (Fig. 5).  
 We next aligned individual CH2 domains of the closed di-sFc, open di-sFc, wtFc 
(3AVE) and the 4BYH sFc structures to compare the orientations of hydrophobic side 
chains (Phe241 and Phe243) adjacent to the N-linked glycan attached to Asn297 (Fig. 
7a). No major changes were observed in the overall fold of the CH2 domains, and only 
minor changes were found in the Phe243 side chain orientation. However, larger 
changes were observed in the Phe241 side chain, which was rotated ~90 compared to 
Phe241 in other Fc structures (Fig. 7b). Typically the aromatic rings of the Phe241 and 
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Phe243 side chains were stacked with respect to each other; however in both CH2 
domains of the closed and open di-sFc structures, Phe241 adopted a different 
conformation such that it was no longer stacked with Phe243 (Fig. 7b,c and Fig. S4). 
The Phe241 side chain was not involved in crystal contacts in any of the structures (data 
not shown); thus these differences were not related to crystal packing. Although the 
Asn297-linked N-glycan is adjacent to Phe241 and Phe243, no major differences were 
observed in the glycan conformation (Fig. 7a), thus the Phe241 side chain orientation did 
not affect the glycan conformation.  
 
Structure of F241A Fc 
We also solved a 2.2 Å resolution crystal structure of F241A Fc (space group P212121; 
one molecule per asymmetric unit) and compared it to wtFc and sFc structures and to 
PDB code 4BM7, a previous F241A Fc structure [23] (Fig. 8a, b). On chain A of the new 
F241A Fc structure, there was ordered electron density for residues Pro230 to Leu443, 
which included part of the hinge region (Glu216 to Pro230 for human IgG1 proteins) that 
normally links the Fab to the N-terminus of the Fc region (Fig. 8c). By contrast, the first 
ordered residue on both chains of wtFc structures was usually Leu234, Leu235, Gly236, 
Gly237, or Pro238 (PDB codes: 1H3X, 3AVE, 2DTS, 3DO3, 1FC1 and 1HZH), and the 
first ordered residue of the F241A B chain was Gly237. The hinge region was also 
disordered in the 4BM7 F241A Fc structure (the first ordered residues were Gly237 on 
chain A and Pro238 on chain B). At Asn297, six ordered glycan residues were modeled 
on chain A and nine residues on chain B of the new F241A structure (Fig. 6), but sialic 
acids were not visible in the new F241A or the 4BM7 F241A structures although the 
F241A glycans included both mono- and disialylated species [23] (Fig. 2 and Fig. 8b). 
Because N-glycans were not completely resolved even in the di-sFc structure, which 
was solved from crystals containing Fc protein with completely homogeneous N-glycans, 
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we cannot use the F241A Fc structures to determine the compositions of N-glycans in 
the F241A Fc crystals. Therefore it is not possible to determine whether a defined glycan 
species crystallized from the heterogeneous protein preparations used to produce both 
of the F241A Fc structures and all of the wtFc structures.  
 Comparison of the CH2 domain separations of the F241A Fc structure with other 
Fc structures showed that the new F241A Fc structure was similar to wtFc structures 
and the open di-sFc structure, but substantially more closed than the 4BM7 F241A Fc 
(Fig. 5, Table 1). (Because portions of the chain B CH2 domain of the 4BM7 F241A Fc 
structure were disordered, including the Asn297-linked glycan and residues 264-274 (BC 
loop), 296-300 (C’E loop), and 324-332 (FG loop), we could not measure all of the inter-
chain distances in the 4BM7 F241A Fc structure.) This large degree of difference in 
F241A Fc conformations is similar to that observed for di-sFc conformations but distinct 
from wtFc conformations. Since both of the F241A Fc structures (the structure reported 
here and the 4BM7 structure) were derived from proteins that were partially sialylated, 
this observation is consistent with the suggestion that a greater degree of conformational 
heterogeneity is available to sialylated Fc proteins than to wtFc with conventional 
glycosylation species. Alternatively, or perhaps in addition, the F241A substitution itself 
could result in greater conformational heterogeneity.  
 
DISCUSSION 
The Fc regions of IgGs can function to either promote or suppress the 
inflammatory response. Previous studies have shown that the Asn297-linked N-glycan 
composition is a determining factor in function [12; 31]. Both biochemical and in vivo 
studies have shown that sialylation of the Fc glycan is essential for the anti-inflammatory 
activity of IVIG [2; 9; 12]. Here we compared structures of wtFc, which carries mostly 
asialylated N-glycans, to sialylated forms of Fc, both a fully disialylated form produced by 
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chemoenzymatic glycoengineering, and an F241A mutant form of Fc. Compared with 
wtFc, the Asn297-linked N-glycan of F241A and F243A Fc showed increased mono- and 
disialylated products when the protein was expressed in mammalian cells. This suggests 
that IgGs with an F241A mutation may be effective anti-inflammatory molecules due to 
increased sialylation.  
Our analyses of the wtFc proteins produced in two different mammalian cell lines 
demonstrated that the Asn297-linked N-glycans were mainly G0F, G1F and G2F 
glycoforms, consistent with previous studies [23], thus we assume a similar composition 
for the N-glycans on the relatively structurally-invariant wtFc structures in the pdb. Not 
only are these glycans mostly asialylated, they also contain only a small percentage of 
digalactosylated forms. In a systematic comparison of wtFc structures reported here and 
previously, we found only small deviations in the “openness” of the Fc, evaluated by the 
distance between the partner CH2 domains in the Fc dimer, despite different crystal 
packing environments, however, we noted that certain glycan species cause increased 
variation in crystal structures. For example, the F241A Fc structure reported here and 
one described previously [23] showed a larger degree of variation in CH2 domain 
orientations than seen in a survey of seven wtFc structures. Other glycovariants of Fc, 
including a recent structure of a digalactosylated form of wtFc [32], also showed a larger 
degree of conformational variability as assessed by differential CH2 domain separations.  
Similar to the partially sialylated F241A Fc structures, crystal structures of 
sialylated wtFc (sFc) have been found in several conformations. In our crystal structure 
of fully disialylated Fc, we found both open and closed CH2 domain conformations in the 
same crystal, and a previously published sFc structure [30] revealed a conformation 
similar to the canonical wtFc structures, again suggesting a large degree of inter-domain 
flexibility of sialylated forms of Fc compared to the relatively invariant structures of 
asialylated wtFc.  
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Recent molecular dynamics simulations showed a wide range of conformations 
that Fc can adopt [32]. Here we have documented a greater flexibility of glycovariant 
forms of Fc that may be key to the ability of the Fc region of IgG to modulate 
inflammatory and anti-inflammatory activities mediated by glycan differences. Further 
structural investigations of how glycan composition and conformational flexibility affect 
binding to Fc receptors that mediate differential activities will be critical to understanding 
the significance of these results.  
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Figure legends 
Fig. 1. IgG, Fc and glycan structures. (a) Schematic structure of IgG1. (b) Ribbon 
diagram of wtFc (PDB: 3AVE) with Asn297-linked N-glycans shown as sticks. Glycan 
residues are colored as in panel c. (c) Schematic of an Asn297-linked N-glycan. The 
biantennary glycan consists of a mannose (Man) and N-acetylglucosamine (GlcNAc) 
core that can be modified by addition of core fucosylation (Fuc), a bisecting GlcNAc, 
terminal galactose (Gal) and sialic acid (NeuNAc).  
 
Fig. 2. HPAEC-PAD analysis of PNGase F-released N-glycans of IgG Fc proteins. (a) 
wtFc expressed in HEK cells. (b) wtFc expressed in CHO cells. (c) F241A Fc expressed 
in HEK cells. (d) F243A expressed in HEK cells. (e) di-sFc prepared by chemoenzymatic 
glycoengineering of an Fc fragment isolated after papain cleavage of Rituximab. The 
amounts of mono- and disialylated N-glycans are shown. * indicates a mixture of 
heterogeneous monosialylated glycoforms. † indicates a mixture of heterogeneous 
disialylated glycoforms. ‡ indicates a satellite peak due to epimerization of reducing end 
GlcNAc to ManNAc. 
 
Fig. 3. SDS-PAGE (left) and SNA blot (right) of Fc proteins expressed in HEK cells. 
wtFc, F241A Fc and F243A Fc were expressed as Fc fragments; di-sFc was prepared 
by papain cleavage from Rituximab IgG.  
 
Fig. 4. Comparison of wtFc and sFc structures. Fc structures were aligned by 
superimposing the CH3 domains. (a) Alignment of wtFc structures (the wtFc structure 
solved in this study plus PDB entries 1HZH, 1FC1, 2DTS, 3AVE, 1H3X, and 3DO3). (b) 
Alignment of closed and open structures of di-sFc (this study), sFc (PDB 4BYH), and 
wtFc (PDB 3AVE).  
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Fig. 5. Comparison of CH2 domain separation in Fc structures. Left: location of C atoms 
for Pro238, Phe241, Arg301, and Pro329 (red spheres) and Asn297 (blue spheres) 
indicated on the CH2 domains of wtFc (PDB: 3AVE). CH2 domain separation in individual 
Fc structures was evaluated by measuring distances (dotted lines) between the 
corresponding red spheres on each chain. Right: Differences in CH2 domain separation 
relative to a reference wtFc structure (3AVE) plotted for the each set of paired C 
positions in the indicated category of Fc structure. When a structure category had more 
than one member, the mean and standard deviation are superimposed upon the values. 
Fc structure categories are as follows: wtFc (structure solved in this study plus PDB 
entries 1H3X, 3AVE, 2DTS, 3DO3, 1FC1, 1HZH), wtFc high salt (1H3Y), glycovariant 
(GV) Fcs (1H3W, 1H3U, 1H3V, 2WAH, 4ACP, 3DNK,4KU1 and 3S7G), mutant (mut) 
Fcs (2QL1, 3FJT, and 3C2S), Fcs complexed with other proteins (com Fc) (3D6G, 1L6X, 
1OQO, 1OQX, 1DN2, 1FCC, 1FC2, 1E4K, 1T83, 1T89, 3AY4, 3RY6, 3SGK and 3SGJ), 
di-sFc closed, di-sFc open, sFc (4BYH), F241A Fc (this study), and F241A Fc (4BM7). 
 
Fig. 6. Comparison of ordered glycans on Fc structures. 2Fo-Fc electron density 
(contoured at 0.7σ) from an annealed omit map in the region of the Asn297-linked N-
glycan is shown for both chains of di-sFc closed, di-sFc open, F241A Fc, and wtFc (this 
study). Ordered glycan residues are shown schematically below each map using the 
colors and shapes defined in Fig. 1c.  
 
Fig. 7. Comparison of glycan and protein residue conformations in sFc and wtFc 
structures. (a) Alignment of Asn297-linked N-glycans of di-sFc closed (blue), di-sFc open 
(green), F241A Fc (magenta), F241A Fc 4BM7 (yellow), sFc 4BYH (cyan), wtFc from 
this study and wtFc 3AVE (both gray). The side chains of Phe241 and Phe243 are 
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shown in red on the CH2 domain of wtFc. (b) Alignment of Phe(Ala)241–Leu242–Phe243 
region in the structures of di-sFc closed (blue), di-sFc open (green), F241A Fc 
(magenta), F241A Fc 4BM7 (yellow), sFc 4BYH (cyan), wtFc from this study and wtFc 
3AVE (both gray).(c) 2Fo-Fc electron density (contoured at 0.7σ) from an annealed omit 
map in the region Phe243 and Phe241 side chains for the di-sFc structures. See also 
Fig. S5. 
 
Fig. 8. Comparison of F241A Fc structures. (a) Superimposition of C traces of F241A 
Fc (this study) (magenta) and F241A Fc (PDB 4BM7) (cyan). Locations of C atoms at 
position 241 of each chain are shown as green spheres. (b) 2Fo-Fc electron density 
(contoured at 0.7σ) from annealed omit maps for F241A Fc (this study) and F241A Fc 
(PDB: 4BM7). Ordered glycan residues are shown schematically below each map using 
the colors and shapes defined in Fig. 1c. (c) 2Fo-Fc electron density (annealed omit 
map) of an ordered portion of the hinge region (blue) on chain A contoured at 0.6σ. (d) 
2Fo-Fc electron density (contoured at 0.7σ) from annealed omit maps in the region of 
the Phe243 and Ala241 side chains for the structures of F241A Fc (this study) (left) and 
F241A Fc (PDB: 4BM7) (right). 
 
 
 
METHODS 
Protein Expression and Purification 
 Fc proteins were expressed in transiently-transfected HEK 293-6E suspension 
cells (F241A Fc and F243A Fc) or stably-transfected Chinese hamster ovary cells (wtFc) 
as described [21; 33]. Fc proteins were isolated from harvested supernatants using 
protein A chromatography (GE Healthcare) followed by size exclusion chromatography 
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in 25 mM Tris-Cl pH 7.5, 100 mM NaCl on a Superdex 16/60 gel-filtration column (GE 
Healthcare). Fractions corresponding to the Fc were pooled and used for crystallization 
and glycan analysis.  
 Fc protein for di-sFc production was prepared by papain cleavage of Rituximab 
(Rituxan®) (Genentech, Inc., California), a human IgG1 Fc. Rituximab (40 mg) was 
buffer exchanged into 10 mM Tris-HCl pH 7.5 overnight at 4ºC. Dialyzed material was 
concentrated to 20 mg/ mL (~2 mL). Immobilized papain (Thermo Scientific) was 
prepared following the manufacturer’s protocol. 1 mL of immobilized papain slurry (50% 
immobilized papain) was added to the Rituximab solution. The reaction was incubated at 
37ºC for 5 hours while continuously inverting the sample tube. The resin was removed 
using a spin column and the filtrate was loaded over a protein A column (2 x 5 mL) that 
was pre-equilibrated with 10 mM Tris-HCl, pH 7.5. The column was washed with 10 
column volumes of 10 mM Tris-HCl, pH 7.5 until no protein was detected in the flow 
through. Bound Fc was eluted in 4 mL of a 100 mM citric acid solution pH 3.5. Eluted 
fractions were quickly neutralized using a 1.5 M solution of Tris-HCl pH 8.8. Purified Fc 
was combined, concentrated and injected over a 40 mL (4 x 10 mL) HiTrap desalting 
column (GE Healthcare) pre-equilibrated in a phosphate buffered saline solution (pH 7.4) 
to give 10 mg of Fc. wtFc for crystallization was prepared similarly by papain digestion of 
the anti-HIV-1 IgG1 antibody 21c (expressed in HEK 293-6E cells as described [33]).  
 
Preparation of disialylated Fc (di-sFc) 
Purified Fc (10 mg) prepared by papain cleavage of Rituximab IgG was treated with 30 
µg of recombinant S. pyogenes EndoS [22] for 1 hr at 37ºC. Analysis by LC-MS showed 
complete cleavage of the glycan. The deglycosylated Fc was isolated using a Sephacryl 
S-200 HR size exclusion column (GE Healthcare) while monitoring UV absorbance and 
collecting peaks. The fractions containing deglycosylated Fc were pooled and 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 19 
concentrated to give 9 mg of the intermediate (Fucα1,6)GlcNAc-Fc. A solution of 
(Fucα1,6)GlcNAc-Fc (5 mg) and sialoglycan-oxazoline (5 mg) buffered with Tris-HCl 
(100 mM, pH 7.0, 0.5 mL) was incubated with EndoS-D233A (200 µg) [22] at 30ºC. 
Aliquots were taken at time intervals for LC-MS analysis of reaction progression. 
Quantitative conversion was achieved in 2 hours. The product was purified using size 
exclusion chromatography as described above. Product fractions were pooled and 
concentrated to give di-sFc (4.5 mg). LC-MS data: calculated for (Fucα1,6)GlcNAc-Fc 
monomer, MW = 25287.3 Da; found MW = 25289 Da (deconvolution data obtained from 
the original spectrum). Calculated for fully sialylated N-glycan-Fc monomer, MW = 
27288.9 Da; found MW = 27289 Da (deconvolution data). 
 
N-glycan analysis 
25 µg of each Fc fragment was treated with PNGase F (NEB) in a G7 buffer (0.5 
M sodium phosphate, pH 7.5) following the manufacturer’s instructions. Samples were 
purified over a CarboPac PGC column and analyzed using HPAEC-PAD on a Dionex 
ICS 5000 with a CarboPac PA200 column. The N-glycans were eluted in 100 mM NaOH 
with the following gradient conditions: 0-10 mM NaOAC in 20 min and then 10-100 mM 
NaOAc in 20 min. Peaks were assigned using N-glycan standards purified from PNGase 
F digestions of Rituximab, sheep IgG (Sigma), and sialylglycopeptide (SGP) from 
chicken egg yolk. 
 
Monosaccharide compositional analysis of putative O-glycans 
 PNGase F-treated Fc proteins lacking N-glycans were dissolved in 3M TFA in 
screw cap vials. The tubes were sealed and incubated at 100 oC for 4 hours. Tubes were 
then cooled to 25 oC, and the reaction mixture was evaporated to dryness in a 
SpeedVac. The dried samples were dissolved in water and subjected to HPAEC-PAD 
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analysis on a CarboPac PA10 column. Monosaccharides were eluted with 18 mM NaOH 
and detected with pulsed amperic detection with a gold electrode using a standard 
monosaccharide waveform. For analysis of sialic acids from putative O-glycans, the de-
N-glycosylated Fc proteins were treated with neuraminidase (NEB) for 16 hours in the 
desialylation buffer provided by the manufacturer (NEB). The samples were then 
subjected to HPAEC-PAD analysis on a CarboPac PA10 column using a sialic acid 
standard (Sigma) for detection and quantification.  
 
LC-ESI-MS Analysis of Fc fragments 
Fc fragments and PNGase F-treated Fc fragments were reduced with 50 mM TCEP at 
37 °C for 15 minutes and subjected to LC-ESI-MS analysis on an Agilent C8 column 
eluted with a gradient of 0-60% acetonitrile in 10 min.  
 
Crystallization and data collection 
 Crystals of di-sFc (space group P21; a = 52.73 Å, b = 154.22 Å, c = 66.12 Å,  = 
110.78˚; two Fc dimers per asymmetric unit) were grown in sitting drop vapor diffusion 
by mixing equal volumes of di-sFc (6.15 mg/ml) with a solution containing 0.2 M 
magnesium chloride, 0.1 M sodium acetate pH 5, and 20% (w/v) PEG 6000 at 20°C. 
Crystals were cryopreserved in well solution supplemented with 30% glycerol. Data were 
collected to 3.0 Å resolution at beamline 8.2.1 of the Advanced Light Source (ALS) at 
Lawrence Berkeley National Laboratory (LBNL).  
 Crystals of wtFc (space group P212121; a = 49.56 Å, b = 79.69 Å, c = 138.06 Å; 
one Fc dimer per asymmetric unit) were grown in sitting drop vapor diffusion by mixing 
equal volumes of protein with a solution containing 0.1 M sodium cacodylate pH 6.5 and 
18% (w/v) PEG 3350 at 20°C. The protein solution contained mainly 21c Fab produced 
by papain digestion of 21c IgG, but contaminating amounts of the Fc crystallized. The Fc 
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crystals were cryopreserved in well solution containing 30% glycerol. F241A Fc crystals 
(space group P212121; a = 57.91 Å, b = 74.70 Å, c = 113.71 Å; one Fc dimer per 
asymmetric unit) were grown in hanging drops by mixing F241A Fc (4.4 mg/ml) with 30% 
PEG 1500 at 20°C and cryopreserved in well solution containing 25% glycerol. Data 
were collected for both wtFc (2.4 Å resolution) and F241A Fc (2.2 Å resolution) at 
beamline 12-2 of the Stanford Synchrotron Radiation Lightsource (SSRL). 
 
Data Processing and Structure Determination 
 Diffraction data were processed and indexed using iMosflm [34] and integrated 
and scaled using POINTLESS and SCALA [35; 36]. In addition to considering I/I and 
completeness of the highest resolution shell, we used the CC1/2 statistic [37] (correlation 
coefficient between two random halves of the data set where CC1/2 > 10%) to determine 
the high-resolution cutoff for our data. We used Phenix [38] to compute CC1/2 values. 
Structures were solved by molecular replacement using PHASER [39] and published Fc 
structures as search models (PDB 1H3X for F241A Fc and wtFc; 3D03 for di-sFc). 
Modeling was done using COOT [40] using composite omit maps for building glycans 
and nearby protein residues in the CH2 domains. Crystallographic refinement was done 
using the Phenix crystallography package [38] by refining individual B factors for the 
higher resolution structures (F241A Fc and wtFc; 2.2 Å and 2.4 Å resolution, 
respectively). For the lower resolution di-sFc structure (3.0 Å resolution), we refined 
group B factors and used non-crystallographic symmetry (NCS) restraints during 
refinement. Because the CH2 domain orientations differed between the two di-sFc 
molecules in the asymmetric unit, the NCS restraints were applied to individual domains 
(CH2 domain residues Phe240 – Ile336, and residues CH3 domain Pro343 – Leu443 on 
each Fc chain). We used PyMol [41] for superposition calculations and molecular 
representations. 
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 The F241A Fc model (Rfree = 23.2%; Rwork = 20.6%) included 421 protein 
residues in the F241A Fc dimer (Pro230 - Leu443 on chain A and Gly237- Leu443 on 
chain B), 16 glycan residues (GlcNAc1-Gal6, Fuc12 on chain A and GlcNAc1-GlcNAc8, 
Fuc12 on Chain B), and 351 water molecules. No electron density was observed for 
residues Thr225 and Cys226 of the Fc hinge or for Man7-NeuNAc10 or Gal9-NeuNAc11 
in the N-linked glycan of chain A or B, respectively. The wtFc model (Rfree = 26.4%; Rwork 
= 21.1%) included 415 protein residues in the wtFc dimer (Pro238-Ser444 on chain A 
and Gly236-Pro443 on chain B), 13 glycan residues (GlcNAc1-GlcNAc5, Man7, 
GlcNAc8, Fuc12 on both chains A and B), and 165 water molecules. No electron density 
was observed for residues Cys226 to Pro230 of the Fc hinge or for Gal6, Gal9 or 
NeuNAc10 on the N-glycan. Side chains were disordered for residues 269 and 311 on 
chain A and 246, 269, 311, and 326 on chain B. The di-sFc structure (Rfree = 28.0%; 
Rwork = 26.0%) included two conformationally distinct Fc dimers (chains A and B in the 
closed dimer and chains C and D in the open dimer). The closed di-sFc dimer model 
included 414 protein residues (Gly236 - Ser444 and Pro238 - Ser444 on chains A and B, 
respectively) and 16 glycan residues (GlcNAc1- GlcNAc5, Man7, GlcNAc8 on chain A 
and GlcNAc1 - GlcNAc8, NeuNAc11 on chain B). No electron density was observed for 
residues Glu225 to Pro230 of the Fc hinge or for Gal6, Gal9 - NeuNAc10 (chain A) or 
Gal9, NeuNAc11 on (chain B) in the N-linked glycan. Side chains were disordered for 
residues 246, 251, 258, 268, 269, 272, 274, 280, 288, 292, 294, 295, 296, 301, 307, 
317, 326, 340, 355, 360, 365, 386, 410, 414, 416, 418, and 433 on chain A and 248, 
269, 272, 274, 283, 298, 314, 326, 340, 355, 384, and 386 on chain B.  The open di-sFc 
dimer model included 410 protein residues (residues Pro238 - Leu443 on each Fc chain) 
and 17 glycan residues (GlcNAc1-GlcNAc8, NeuNAc11 on chain C and,GlcNAc1-
GlcNAc8 on chain D). No electron density was observed for residues Cys226 to Pro230 
of the Fc hinge, Ala327-Ile332 (chain C), Val264-Asp270 (Chain D) or for Gal9, 
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NeuNAc10 (chain C) or Gal9-NeuNAc11 (chain D) in the N-linked glycan. Side chains 
were disordered for residues 242, 246, 268, 269, 270, 272, 274, 285, 288, 290, 293, 
295, 300, 301, 309, 311, 312, 320, 340, 342, 360, 380, 384, 386, 416, 418, 419, and 433 
on chain C and 248, 263, 272, 276, 286, 288, 290, 295, 301, 302, 323, 332, 334, 360, 
377, 384, 386, and 439 on chain D.  
 
ACCESSION NUMBERS 
Atomic coordinates and structure factors have been deposited in the Protein Data Bank 
with accession codes 4Q7D (wtFc), 4Q6Y (di-sFc), and 4Q74 (F241A Fc).  
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Table 1: Distance measurements between CH2 domains in IgG1 Fc structures 
PDB 
ID Protein 
Category 
How 
expressed 
Space 
Group 
Cell  
Dimensions  
a,b,c (Å)  
[ angle; deg] 
Resolution 
(Å) 
Pro238 
Cα (Å) 
Phe241 
Cα (Å) 
Arg301 
Cα (Å) 
Pro 329 
Cα (Å) 
1H3X Fc (G0F)2 wtFc IgG P212121 50, 80, 139 2.4 19.7 21.9 33.9 22.6 
3AVE Fc Fucosylated wtFc IgG P212121 50, 78, 144 2.0 19.3 21.8 32.3 25.1 
2DTS Fc Defucosylated wtFc IgG P212121 49, 78, 143 2.2 18.6 21.5 32.2 24.2 
3DO3 Fc wtFc IgG P212121 50, 80, 139 2.5 20.1 22.4 32.8 23.5 
1FC1 Fc wtFc IgG P212121 50, 80, 146 2.9 19.6 23.5 34.2 26.8 
N/A Fc wtFc IgG P212121 50, 80, 138 2.4 20.2 21.9 32.9 22.9 
1HZH Intact  IgG1  wtFc IgG H32 271, 271, 175 2.7 21.1 22.2 33.6 23.9 
1H3Y Fc high salt Fc high salt IgG P6122 153, 153, 117 4.1 16.7 22.3 25.9 29.6 
4KU1 Fc (G2F)2 glycovariant  IgG P212121 49, 80, 128 1.9 21.3 23.3 33.2 29.1 
1H3V Fc (G2F)2 glycovariant  IgG P212121 49, 81, 142 3.1 19.3 23.2 32.9 26.9 
1H3W Fc (G2F)2 glycovariant  IgG C2221 50, 149, 76 2.9 22.9 26.1 35.9 33.8 
1H3U Fc (M3N2F)2 glycovariant  IgG P212121 49, 80, 144 2.4 19.2 22.0 32.7 24.2 
2WAH Fc (Man9NAG2 ) glycovariant  Fc P212121 49, 75, 149 2.5 30.2 29.8 42.8 36.4 
4B7I Fc Hybrid glycan glycovariant Fc P212121 49, 73, 141 2.4 36.1 33.2 47.0 41.1 
4ACP Fc (GlcNAc) glycovariant  Fc C2 69, 111, 78, 108° 2.5 11.4 17.8 26.2 N/A 
3DNK Fc deglycosylated glycovariant  IgG P212121 49, 78, 147 2.8 24.8 25.0 37.4 27.6 
3S7G Fc deglycosylated glycovariant  Fc P1 66, 66, 78 3.1 10.7 16.8 25.8 18.9 
2QL1 Fc DLE mutant mutant Fc Fc C2221 50, 147, 74 2.5 27.6 28.5 37.2 39.3 
3FJT Fc YTE mutant mutant Fc Fc P212121 50, 80, 146 2.5 20.0 22.1 33.4 25.3 
3C2S Fc FES mutant mutant Fc IgG C2221 50, 147, 75 2.3 28.1 28.8 38.1 35.9 
3D6G Fc: protein A  complex IgG P212121 50, 79, 139 2.3 19.2 22.2 32.9 24.3 
1L6X Fc: Z34C complex IgG C2221 54, 125, 90 1.7 22.2 22.8 33.9 26.6 
1OQO Fc (G0): mini Z complex ? P21212 86, 126, 55 2.3 20.0 22.1 33.1 24.3 
1OQX Fc (G2): Z34C complex ? P21212 87, 126, 54 2.6 20.1 21.8 33.0 24.7 
1DN2 Fc: peptide complex IgG P21 68, 61, 68, 104° 2.7 26.1 27.0 37.4 31.9 
1FCC Fc: Protein G  complex IgG P43212 111, 111, 160 3.2 22.1 26.0 34.5 34.7 
1FC2 Fc: protein A  complex IgG P3121 71, 72, 147 2.8 18.3 22.0 31.4 27.7 
1E4K Fc :FcgRIIIB complex IgG P6522 115, 115, 299 3.2 25.0 25.7 36.7 30.3 
1T83 Fc :FcgRIIIB complex IgG P212121 73, 102, 123 3.0 24.8 26.1 36.9 31.3 
1T89 Fc :FcgRIIIB complex IgG P6522 115, 115, 301 3.5 24.5 25.9 37.3 30.6 
3AY4 
Fc afucosylated: 
FcRIIIA 
complex 
IgG P41212 77, 77, 350 2.2 25.2 25.7 36.3 30.8 
3RY6 Fc: FcRIIa complex IgG C2221 153, 256, 58 3.8 20.5 23.1 34.4 31.4 
3SGK 
afucosylated Fc: 
FcγRIIIA 
complex 
IgG P212121 67, 88, 141 2.4 25.6 26.6 37.4 32.6 
3SGJ 
fucosylated Fc: 
FcγRIIIA 
complex 
IgG P212121 67, 88, 140 2.2 25.6 26.3 36.9 32.3 
N/A di-sFc closed N/A IgG P21 53, 154, 66, 111° 3.2 12.8 17.8 26.4 21.9 
N/A di-sFc open N/A IgG P21 53, 154, 66, 111° 3.2 20.1 21.7 31.2 N/A 
4BYH sFc N/A Fc P6122 153, 153, 112 2.3 17.6 21.8 26.2 30.5 
N/A F241A Fc N/A Fc P212121 58, 75, 114 2.2 23 25.1 33.8 31.1 
4BM7 F241A Fc N/A Fc P212121 49, 73, 136 1.9 34 31.7 45.1 N/A 
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HIGHLIGHTS 
 What structural changes occur with sialylation cause IgG anti-inflammatory 
state? 
 Sialylated Fc structures exist in open and closed conformations.  
 The sidechain of Phe241 can adopt an altered conformation in sialylated Fc. 
 F241A mutation causes increased inter-domain flexibility in Fc crystal structures. 
 
 
 
